Search Clinical Trials in the European Union

Duration
Visits
Confirmation phase (III)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
81-100 of 1,307 trials

Chronic Lymphocytic Leukemia: Nemtabrutinib Study

We are comparing a new treatment called nemtabrutinib to standard options for patients with untreated chronic lymphocytic leukemia. The study aims to find out which treatment works better and is safer.

Small Lymphocytic Lymphoma (SLL) / Chronic Lymphocytic Leukemia (CLL)6-12 monthsConfirmation phase (III)>20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Advanced Non-Clear Cell Kidney Cancer: XL092 + Nivolumab

We are studying a new treatment combination for patients with advanced or metastatic non-clear cell kidney cancer. The goal is to see if it works better and is safer than the standard treatment.

Advanced Non-Clear Cell Renal Cell Carcinoma>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

COVID-19 Treatment: LTX-109 Nasal Spray Study

We are testing a new nasal spray for people with COVID-19 or similar symptoms to see if it helps them recover faster and clear the virus. The study will also monitor safety and overall wellbeing during treatment.

Respiratory Tract InfectionCOVID-19COVID-like Illness≤3 monthsEfficacy phase (II)Confirmation phase (III)Investigational MedicinesPartially RemoteInfectious DiseasesPulmonology

Irritable Bowel Syndrome: Ebastine vs. Mebeverine

We are comparing the effectiveness of ebastine and mebeverine for treating irritable bowel syndrome. The study also looks at how these treatments impact quality of life for patients.

Irritable Bowel Syndrome3-6 monthsConfirmation phase (III)≤5 visitsStandard MedicinesGastroenterologyInternal Medicine

Metreleptin for Young Children with Generalized Lipodystrophy

We are studying whether metreleptin can help children under 6 years old with generalized lipodystrophy and related diabetes. The trial will also look at its effects on quality of life and other health markers.

Generalized Lipodystrophy1-2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteDermatologyEndocrinology

Marginal Zone Lymphoma: Mosunetuzumab-Lenalidomide Study

We are investigating whether the combination of Mosunetuzumab and Lenalidomide is more effective than standard treatments for patients with relapsed or refractory Marginal Zone Lymphoma. The study aims to assess how well this new treatment works and its safety.

Marginal Zone Lymphoma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

Remifentanil for Intubation in Newborns

We are studying the best dose of remifentanil to safely sedate newborns during intubation. Our goal is to ensure effective sedation with minimal side effects.

Stable Neonates Requiring Intubation>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInternal MedicineOtolaryngologyPediatrics

Generalized Myasthenia Gravis: Ravulizumab for Kids

We are studying the effects of Ravulizumab in children with Generalized Myasthenia Gravis to see how well it works and its safety. This trial will help us understand if it improves their quality of life.

Generalized Myasthenia Gravis3-6 monthsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNeurologyPediatrics

Prostate Cancer Imaging: PSMA-PET vs. mpMRI

We are comparing two imaging methods to see which better identifies critical areas in high-risk prostate cancer. This study may help improve diagnosis and treatment planning for patients.

Prostate Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncologyUrology

Polymyalgia Rheumatica: Secukinumab Injection Study

We are studying whether secukinumab, combined with a glucocorticoid taper, can help patients with polymyalgia rheumatica achieve better remission compared to a placebo. This trial also looks at the safety and quality of life for participants.

Polymyalgia Rheumatica1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Asthma in Children: QMF149 vs. Budesonide

We are studying whether QMF149 can improve lung function and reduce asthma symptoms in children aged 6 to under 12 compared to Budesonide. This trial will help us understand which treatment works better for young patients.

Asthma6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPediatricsPulmonology

Inclusion Body Myositis: ABC008 Treatment Study

We are studying the safety and effectiveness of a new treatment called ABC008 for people with Inclusion Body Myositis. The goal is to see if it improves muscle function and strength compared to a placebo.

Inclusion Body Myositis1-2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteNeurologyRheumatology

Gastrectomy: Pancreatic Enzyme Supplementation

We are investigating if taking pancreatic enzymes with meals improves quality of life for patients after gastrectomy. This study aims to see how these enzymes may help in recovery.

Patients after Gastrectomy>2 yearsConfirmation phase (III)Investigational MedicinesGastroenterologyInternal Medicine

Generalized Periodontitis: Valaciclovir Treatment Study

We are investigating whether the antiviral drug Valaciclovir can improve treatment outcomes for people with advanced generalized periodontitis. This study compares its effects to standard treatments and a placebo.

Generalized Periodontitis≤3 monthsConfirmation phase (III)Investigational MedicinesInfectious DiseasesOtolaryngology

Roxadustat for Anemia in Children with Chronic Kidney Disease

We are studying a new treatment for anemia in children and adolescents with chronic kidney disease. The trial will evaluate its effectiveness, safety, and how it impacts daily life.

Nephrogenic Anemia1-2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementHematologyNephrology

Kidney Transplant: Comparing rATG and Basiliximab

We are studying whether rATG is more effective than basiliximab in preventing kidney transplant rejection in sensitized patients without pre-existing antibodies. This trial aims to improve outcomes for kidney transplant recipients.

Kidney Transplant>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesNephrology

Acute Myeloid Leukemia: Comparing Treatment Regimens

We are studying two different conditioning regimens for adults with acute myeloid leukemia before stem cell transplantation. The goal is to see which regimen may improve survival and recovery outcomes.

Acute Myeloid Leukemia in Remission>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesHematology

Crohn's Disease: Risankizumab for Children

We are studying the safety and effectiveness of risankizumab in children aged 2 to under 18 with moderately to severely active Crohn's disease. This trial aims to help those who haven't responded to other treatments.

Crohn's Disease>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteGastroenterologyInternal Medicine

H3 K27M-Mutant Diffuse Glioma: ONC201 Treatment Study

We are studying the effects of ONC201 in patients with H3 K27M-mutant diffuse glioma after radiotherapy. The goal is to see if it improves outcomes compared to a placebo.

H3 K27M-Mutant Diffuse GliomaConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteOncology

Zilucoplan for Children with Generalized Myasthenia Gravis

We are studying the long-term safety of zilucoplan in children with generalized myasthenia gravis who participated in an earlier trial. This research aims to understand how well the treatment works and its effects over time.

Myasthenia GravisConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNeurologyPediatrics